Medigoxin
From Wikipedia, the free encyclopedia
Medigoxin
|
|
Systematic (IUPAC) name | |
4-[(3S,5R,8R,9S,10S,12R,13S,14S)-12,14- Dihydroxy-3- [(2R,4S,5S,6R)-4-hydroxy- 5-[(2S,4S,5S,6R)-4-hydroxy- 5-[(2S,4S,5S,6R)-4-hydroxy- 5-methoxy-6-methyl-oxan-2-yl]oxy- 6-methyl-oxan-2-yl]oxy-6-methyl- oxan-2-yl]oxy-10,13-dimethyl- 1,2,3,4,5,6,7,8,9,11,12,15,16,17- tetradecahydrocyclopenta[a]phenanthren- 17-yl]-5H-furan-2-one |
|
Identifiers | |
CAS number | |
ATC code | C01 |
PubChem | |
Chemical data | |
Formula | C42H66O14 |
Mol. mass | 794.965 |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Medigoxin (or metildigoxin) is a cardiac glycoside closely related to digoxin.
|